Elucidation of the variability in consistency of pharmacopoeia quality petrolatum. (3rd April 2017)

• Record Type: Journal Article
• Authors: van Heugten, Anton Joris Pancras; Versluijs-Helder, Marjan; Vromans, Herman
• Is Part Of: Drug development and industrial pharmacy. Volume 43:Number 4(2017)
• Page Start: 595
• Page End: 599
• Publication Date: 2017-04-03
• Subjects: Petrolatum -- crystallinity -- X-ray -- yield stress -- thermal history; Pharmaceutical chemistry -- Periodicals; Pharmaceutical industry -- Periodicals; Drug Industry -- Periodicals; Technology, Pharmaceutical -- Periodicals; 615.05
• DOI: 10.1080/03639045.2016.1274902
• Languages: English
• ISSNs: 0363-9045

Abstract

Abstract: The Pharmacopeia monograph for petrolatum poorly defines the material's physical properties. Indeed, differences between petrolatum grades can be substantial; yield stress varies between 65 and 280 Pa which can be compared with the consistency of respectively thin cream or thick ointment. This variation is not only due to differences in composition or refining process but also as a result of different processing; for example, thermal history influences petrolatum structure considerably. Slow cooling of petrolatum resulted in a yield stress of 26 Pa and fast cooling in 79 Pa. X-ray showed that crystallinity was 0.7% for the first cooling case and 1.5% for the second one. Crystallite size was estimated to be 20–50 nm. To investigate if this relatively small difference in crystallinity may induce the difference in consistency, 15 nm SiO2 particles were added to petrolatum. Indeed, a small increase in SiO2 concentration led to a major increase in yield stress. This was argued to be due to the small size of the particles, resulting in a large increase in absolute number of particles. The Pharmacopeia does not unambiguously define the pharmaceutical excipient petrolatum. As a consequence, the formulator has to take care of selecting the appropriate grade as well as to carefully control the processing of the material in order to achieve a consistent pharmaceutical product.